Evidence map›Paper›PMID 40887856›Full record

ArticleClinical and translational medicine2025

Dissecting cross-lineage tumourigenesis under p53 inactivation through single-cell multi-omics and spatial transcriptomics.

Xinru Wang, Yuqing Mei, Xueyi Wang, Hanyu Wu, Renying Wang, Peijing Zhang, Guodong Zhang, Jiaqi Li, Mengmeng Jiang, Xing Fang and 19 more

Abstract read
In one paragraph

Article in Clinical and translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Xinru WangBone Marrow Transplantation Center of the First Affiliated Hospital and Center for Stem Cell and Regenerative Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Yuqing MeiBone Marrow Transplantation Center of the First Affiliated Hospital and Center for Stem Cell and Regenerative Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Xueyi WangBone Marrow Transplantation Center of the First Affiliated Hospital and Center for Stem Cell and Regenerative Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Hanyu WuBone Marrow Transplantation Center of the First Affiliated Hospital and Center for Stem Cell and Regenerative Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Renying WangBone Marrow Transplantation Center of the First Affiliated Hospital and Center for Stem Cell and Regenerative Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Peijing ZhangBone Marrow Transplantation Center of the First Affiliated Hospital and Center for Stem Cell and Regenerative Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Guodong ZhangBone Marrow Transplantation Center of the First Affiliated Hospital and Center for Stem Cell and Regenerative Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Jiaqi LiBone Marrow Transplantation Center of the First Affiliated Hospital and Center for Stem Cell and Regenerative Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Mengmeng JiangLiangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, Zhejiang, China.
Xing FangBone Marrow Transplantation Center of the First Affiliated Hospital and Center for Stem Cell and Regenerative Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Lifeng MaBone Marrow Transplantation Center of the First Affiliated Hospital and Center for Stem Cell and Regenerative Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Yuan LiaoBone Marrow Transplantation Center of the First Affiliated Hospital and Center for Stem Cell and Regenerative Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Danmei JiaBone Marrow Transplantation Center of the First Affiliated Hospital and Center for Stem Cell and Regenerative Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Haofu NiuBone Marrow Transplantation Center of the First Affiliated Hospital and Center for Stem Cell and Regenerative Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
E WeigaoBone Marrow Transplantation Center of the First Affiliated Hospital and Center for Stem Cell and Regenerative Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Haide ChenBone Marrow Transplantation Center of the First Affiliated Hospital and Center for Stem Cell and Regenerative Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Lei YangBone Marrow Transplantation Center of the First Affiliated Hospital and Center for Stem Cell and Regenerative Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Shuang ZhangBone Marrow Transplantation Center of the First Affiliated Hospital and Center for Stem Cell and Regenerative Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Tingyue ZhangBone Marrow Transplantation Center of the First Affiliated Hospital and Center for Stem Cell and Regenerative Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Yincong ZhouCollege of Life Sciences, Zhejiang University, Hangzhou, Zhejiang, China.
Qi ZhangDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.ORCID 0000-0003-0516-8008
He HuangBone Marrow Transplantation Center of the First Affiliated Hospital and Center for Stem Cell and Regenerative Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Hongwei OuyangZhejiang Provincial Key Lab for Tissue Engineering and Regenerative Medicine, Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cell and Regenerative Medicine, Hangzhou, Zhejiang, China.ORCID 0000-0003-0627-2536
Ming ChenCollege of Life Sciences, Zhejiang University, Hangzhou, Zhejiang, China.
Tingbo LiangDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Jinrong PengMOE Key Laboratory for Molecular Animal Nutrition, College of Animal Sciences, Zhejiang University, Hangzhou, Zhejiang, China.
Jingjing WangBone Marrow Transplantation Center of the First Affiliated Hospital and Center for Stem Cell and Regenerative Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Guoji GuoBone Marrow Transplantation Center of the First Affiliated Hospital and Center for Stem Cell and Regenerative Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Xiaoping HanBone Marrow Transplantation Center of the First Affiliated Hospital and Center for Stem Cell and Regenerative Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.ORCID 0000-0003-3201-7635

Funding

Funds for Creative Research Groups of China No.T2121004Key R&D Program of Zhejiang No.2024SSYS0022National Key Research and Development Program 2018YFA0107804National Key Research and Development Program 2018YFA0800503National Natural Science Foundation of China 31930028National Natural Science Foundation of China 32000461National Natural Science Foundation of China 32200534National Natural Science Foundation of China 32271491National Natural Science Foundation of China 32330061Zhejiang Provincial Natural Science Foundation of China LTGC23C070002
6 · The paper itself

Abstract

backgroundTumour suppressor genes, exemplified by TP53 (encoding the human p53), function as critical guardians against tumourigenesis. Germline TP53-inactivating mutations underlie Li-Fraumeni syndrome, a hereditary cancer predisposition disorder characterised by early-onset pan-tissue malignancies. However, the context-dependent tumour-suppressive mechanisms of p53 remain incompletely elucidated. This study aims to investigate the disruption of cellular homeostasis and tumourigenic mechanisms following p53 inactivation across distinct cell lineages.

methodsTrp53 (encoding mouse p53) knockout mouse model was employed to study molecular alterations under p53-deficient conditions. Multi-omics analyses - including single-cell transcriptomics, single-cell ATAC-seq, spatial transcriptomics, whole genome sequencing, and CUT&Tag - were integrated to construct a Trp53 functional cell landscape. Deep learning-based gene network models were employed to reconstruct p53 regulatory networks and simulate in silico perturbations caused by p53 loss.

resultsOur analyses revealed transitional dynamics in immune, stromal, and epithelial cells from normal physiology to p53-deficient states and subsequent tumourigenesis. These transitions implicated critical pathways such as cell cycle regulation, stress response, metabolic reprogramming, and immune modulation, displaying both lineage-conserved and lineage-specific features. Tumour-prone cell populations exhibiting elevated differentiation plasticity were identified across lineages within tumourigenic trajectories. Spatial transcriptomic profiling confirmed the emergence of thymic tumour-initiating T-cell clusters characterised by deterministic chromatin architectural disruptions under p53-loss pressure. Notably, we uncovered a recurrent upregulation signature of ribosomal protein genes as an early pivotal molecular event preceding malignant transformation in p53-deficient oncogenesis. Finally, we decoded the p53 downstream regulatory network and computationally evaluated the perturbation effects of genetic inactivation at single-cell resolution.

conclusionsOur results elucidate the multiscale consequences of p53 inactivation while providing valuable resources for understanding tumour predisposition associated with p53-inactivating mutations and developing clinical interception strategies. KEY POINTS: Construction of a Trp53 functional cell landscape utilising single-cell multi-omics and spatial omics technologies. Reconstruction of p53 downstream regulatory relationships with lineage heterogeneity via machine learning-based gene network modelling. Dissection of shared and lineage-specific features during cross-lineage tumourigenesis under p53 deficiency.

Indexed as

CarcinogenesisTumor Suppressor Protein p53AnimalsHumansLi-Fraumeni SyndromeMiceMice, KnockoutMultiomicsSingle-Cell AnalysisTranscriptomeTrp53 protein, mouseTumor Suppressor Protein p53cross‐lineage tumourigenesisknockout cell landscape analysesp53 regulatory networksingle‐cell multi‐omics

Identifiers

PMID40887856
PMCPMC12399789

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.